NRx Files for Zyesami Emergency Use in Critical COVID-19 Patients With Respiratory Failure

Author: Vandana Singh | June 01, 2021 12:15pm

• NRx Pharmaceuticals (NASDAQ:NRXP) has applied with FDA requesting Emergency Use Authorization (EUA) for Zyesami (Aviptadil-acetate) for critically ill COVID-19 patients suffering from respiratory failure.
• Consistent with previously announced top-line data, the study identified a statistically significant increase in the likelihood that patients treated with Zyesami would be alive and free of respiratory failure at 60 days, compared to those treated with placebo, and identified a significantly shorter median hospital stay.
• The study enrolled 196 participants who were randomized and treated with either Zyesami or placebo, in addition to maximal standard of care at 10 US hospitals.
• Patients in earlier stages of respiratory failure (those treated with high flow oxygen) were more likely to survive and recover than those who had already progressed to ventilation.
• However, statistically significant benefits in the prespecified endpoint were demonstrated in both groups.
• NRx previously requested limited EUA for highly co-morbid COVID-19 patients. FDA further requested randomized, prospective data regarding Zyesami, which are represented in this filing.
• Separately, the National Institutes of Health is conducting a confirmatory trial that randomizes patients with COVID-19 respiratory failure to Zyesami versus Gilead Sciences Inc's (NASDAQ:GILD) Veklury (remdesivir) and placebo in a factorial design trial.
• A second nationwide trial to determine if similar benefits may be achieved in critically ill patients with inhaled Zyesami is being conducted on the I-SPY platform, maintained by the Quantum Leap Healthcare Collaborative.
• Price Action: NRXP shares are down 3.8% at $21.16 during the market session on the last check Tuesday.

Posted In: GILD NRXP RLFTF